Roche Products Limited
Records under this name other than patents Roche Products Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Roche Products Limited
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,909,178 | Dalcetrapib for Therapeutic Use conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc. In force · High confidence | In force | High confidence | |
| US 10,711,303 | Cetp Inhibitors for Therapeutic Use conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc. In force · Low confidence | In force | Low confidence | |
| US 11,549,142 | Cetp Inhibitors for Therapeutic Use conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc. In force · Low confidence | In force | Low confidence | |
| US 11,389,457 | Compound and Method for the Prevention of Transmission of Influenza Virus conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc. In force · High confidence | In force | High confidence | |
| US 11,911,394 | Compound and Method for the Prevention of Transmission of Influenza Virus conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc. In force · High confidence | In force | High confidence | |
| US 12,195,547 | Dosing for Combination Treatment with ANTI-CD20/ANTI-CD3 Bispecific Antibody and ANTI-CD79B Antibody Drug Conjugate conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc. In force · High confidence | In force | High confidence | |
| US 12,729,243 | Dosing for Treatment with ANTI-CD20/ANTI-CD3 Bispecific Antibody conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc. In force · Medium confidence | In force | Medium confidence | |
| US 6,784,166 | 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication conveyed to F Hoffmann la Roche AG - now held by Riboscience LLC Term ended Term ended Jun 11, 2022 · High confidence | Term ended | Term ended Jun 11, 2022 | High confidence |
| US 8,648,054 | 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication conveyed to F Hoffmann la Roche AG - now held by Riboscience LLC Lapsed on the fee record Ended Feb 11, 2022 · Low confidence | Lapsed on the fee record | Ended Feb 11, 2022 | Low confidence |
| US 6,660,721 | Anti-Hcv Nucleoside Derivatives conveyed to F Hoffmann la Roche AG - now held by Hoffmann-La Roche Inc. Lapsed on the fee record Ended Dec 9, 2015 · High confidence | Lapsed on the fee record | Ended Dec 9, 2015 | High confidence |